Resectable Malignant Solid Neoplasm Clinical Trials

1 recruiting

Resectable Malignant Solid Neoplasm Trials at a Glance

14 actively recruiting trials for resectable malignant solid neoplasm are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Boston, Los Angeles, and Bethesda. Lead sponsors running resectable malignant solid neoplasm studies include National Cancer Institute (NCI), Mayo Clinic, and University of California, Davis.

Browse resectable malignant solid neoplasm trials by phase

Treatments under study

About Resectable Malignant Solid Neoplasm Clinical Trials

Looking for clinical trials for Resectable Malignant Solid Neoplasm? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Resectable Malignant Solid Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Resectable Malignant Solid Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 1

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI)43 enrolled23 locationsNCT05687110
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmMetastatic Colorectal Carcinoma+2 more
National Cancer Institute (NCI)30 enrolled22 locationsNCT05803382
Recruiting
Phase 2

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)88 enrolled36 locationsNCT05327010
Recruiting
Phase 1

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmPlatinum-Resistant Ovarian High Grade Serous Adenocarcinoma
National Cancer Institute (NCI)55 enrolled5 locationsNCT04585958
Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)66 enrolled6 locationsNCT05687136
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled1 locationNCT07137416
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more
National Cancer Institute (NCI)45 enrolled7 locationsNCT05372640
Recruiting
Phase 1

MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
Mayo Clinic42 enrolled1 locationNCT06911008
Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Metastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Lung Non-Small Cell Carcinoma+24 more
Mayo Clinic324 enrolled3 locationsNCT06349642
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmStage III Pancreatic Cancer AJCC v8+5 more
University of California, Davis52 enrolled1 locationNCT07189195